Cineplex Announces Voting Results for its 2025 Annual and Special Meeting of Shareholders
TORONTO, May 21, 2025 /CNW/ - (TSX: CGX) - Cineplex Inc. ("Cineplex" or the "Company"), Canada's leading entertainment and media company, is pleased to announce that, at its Annual and Special Meeting of Shareholders held today, each of the items of business referred to in its management information circular dated April 7, 2025 (the "Management Information Circular") was approved by Shareholders. The voting results for each item of business are as follows:
Election of Directors:
Each of the individuals listed as nominees in the Management Information Circular was elected as a director of the Company.
Appointment of Auditors:
The appointment of PricewaterhouseCoopers LLP as auditors of the Company and the authorization of the directors to fix their remuneration was approved.
Votes For: 85.52%
Votes Withheld: 14.48%
Advisory Vote on Say-on-Pay:
The non-binding say-on-pay advisory resolution as set forth in the Management Information Circular on the Company's approach to executive compensation was approved.
Votes For: 83.20%
Votes Against: 16.80%
Omnibus Equity Incentive Plan:
The increase in the number of Common Shares which may be issued pursuant to the Omnibus Equity Incentive Plan as set forth in the Management Information Circular was approved.
Votes For: 83.83%
Votes Against: 16.17%
About Cineplex:
Cineplex (TSX: CGX) is a top-tier Canadian brand that operates in the Film Entertainment and Content, Amusement and Leisure, and Media sectors. Cineplex offers a unique escape from the everyday to millions of guests through its circuit of 172 movie theatres and location-based entertainment venues. In addition to being Canada's largest and most innovative film exhibitor, the company operates Canada's favourite destination for 'Eats & Entertainment' (The Rec Room), complexes specially designed for teens and families (Playdium), and an entertainment concept that brings movies, amusement gaming, dining, and live performances together under one roof (Cineplex Junxion). It also operates successful businesses in cinema media (Cineplex Media), digital place-based media (Cineplex Digital Media or CDM), alternative programming (Cineplex Events) and motion picture distribution (Cineplex Pictures). Providing even more value for its guests, Cineplex is a partner in Scene+, Canada's largest entertainment and lifestyle loyalty program.
Proudly recognized as having one of the country's Most Admired Corporate Cultures, Cineplex employs over 10,000 people in its offices and venues across Canada. To learn more, visit Cineplex.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
AI linked to a fourfold increase in productivity growth and 56% wage premium, while jobs grow even in the most easily automated roles: PwC 2025 Global AI Jobs Barometer
Workers see rising wages: AI-skilled workers see average 56% wage premium in 2024, double the 25% in the previous year Confounding expectations, data shows job availability grew 38% in the roles more exposed to AI, albeit below the growth rate in less exposed occupations Industries most exposed to AI saw 3x higher growth in revenue per employee (27%) compared to those least exposed (9%) The skills sought by employers are changing 66% faster in jobs most exposed to AI LONDON, June 3, 2025 /CNW/ -- AI is making workers more valuable, productive, and able to command higher wage premiums, with job numbers rising even in roles considered most automatable, according to PwC's 2025 Global AI Jobs Barometer, released today. The report is based on analysis of close to a billion job ads from six continents. The report finds that since GenAI's proliferation in 2022, productivity growth has nearly quadrupled in industries most exposed to AI (e.g. financial services, software publishing), rising from 7% from 2018-2022 to 27% from 2018-2024. In contrast, the rate of productivity growth in industries least exposed to AI (e.g. mining, hospitality) declined from 10% to 9% over the same period. 2024 data shows that the most AI exposed industries are now seeing 3x higher growth in revenue per employee than the least exposed. Carol Stubbings, Global Chief Commercial Officer, PwC, said: "This research shows that the power of AI to deliver for businesses is already being realised. And we are only at the start of the transition. As we roll out Agentic AI at enterprise scale, we are seeing that the right combination of technology and culture can create dramatic new opportunities to reimagine how organisations work and create value." Job numbers are rising in virtually every type of AI-exposed occupation, even those highly automatable Contrary to some expectations, the data from the report does not show job or wage destruction from AI. While occupations with lower exposure to AI saw strong job growth (65%) in recent years (2019-2024), growth remained robust even in more exposed occupations (38%). Within more exposed occupations, jobs can be further divided into 'automated' (i.e., the job contains some tasks that AI can carry out) and 'augmented' (i.e., where AI helps a human do their job better). Across both classifications between 2019-24, job numbers are growing in every industry analysed, although augmented jobs are generally growing faster. Wages are growing twice as fast in AI-exposed industries Wages are growing twice as fast in industries more exposed to AI versus less exposed, with wages rising in both automatable and augmentable jobs. Jobs which require AI skills also offer a wage premium (over similar roles that don't require AI skills) in every industry analysed, with the average premium hitting 56%, up from 25% last year. Jobs that require such AI skills also continue to grow faster than all jobs – rising 7.5% from last year, even as total job postings fell 11.3%. Joe Atkinson, Global Chief AI Officer, PwC, said: "In contrast to worries that AI could cause sharp reductions in the number of jobs available – this year's findings show jobs are growing in virtually every type of AI-exposed occupation, including highly automatable ones. AI is amplifying and democratizing expertise, enabling employees to multiply their impact and focus on higher-level responsibilities. With the right foundations, both companies and workers can re-define their roles and industries and emerge leaders in their field, particularly as the full gambit of applications becomes clearer." The skills earthquake accelerates – AI is creating deep change in the skills workers need to succeed While the picture on productivity, wages and jobs is broadly positive, the research does highlight the need for workers and businesses to adapt to a much faster pace of change. The skills sought by employers are changing 66% faster in occupations most exposed to AI, up from 25% last year. What it takes to succeed in AI-exposed jobs is changing in other ways. Employer demand for formal degrees is declining for all jobs, but especially quickly for AI-exposed jobs. The percentage of jobs AI augments that require a degree fell 7 percentage points between 2019 and 2024 from 66% to 59%, and 9 percentage points (53% to 44%) for jobs AI automates. The findings show that AI's impact on women and men may be unequal – in every country analysed, more women than men are in AI-exposed roles, suggesting the skills pressure facing women will be higher. Pete Brown, Global Workforce Leader, PwC, said: "AI's rapid advance is not just re-shaping industries, but fundamentally altering the workforce and the skills required. This is not a situation that employers can easily buy their way out of. Even if they can pay the premium required to attract talent with AI skills, those skills can quickly become out of date without investment in the systems to help the workforce learn." The AI business imperative If businesses are to turbocharge their growth and leverage the opportunity afforded by AI, they must put AI front-and-centre, now. The report recommends five key actions for businesses: Use AI for enterprise-wide transformation. Treat AI as a growth strategy, not just an efficiency strategy. Prioritise Agentic AI. Enable your workforce to have the skills to make the most of AI's power. Unlock AI's transformative potential by building trust. About the PwC 2025 Global AI Jobs Barometer The AI Jobs Barometer analysed close to a billion job ads and thousands of company financial reports across six continents to reveal AI's impact on jobs, wages, skills, and productivity. The Barometer includes some of the most recent available data on AI's impact including the latest available job ads and company reports through the end of 2024. We define a job as 'AI-exposed' if it contains many tasks in which AI can be used according to the well-established AI Occupational Exposure index. Definitions: 'More exposed' jobs are the 50% of jobs with greater AI exposure; 'Less exposed' jobs are the 50% of jobs with lower AI exposure; 'Most exposed' jobs are the 25% of jobs with the greatest AI exposure. We use the IMF's methodology to separately analyse AI-exposed jobs that are highly automatable (which means the job contains many tasks AI can perform) versus jobs that are highly augmentable (which means the job contains many tasks in which AI supports human expertise and judgment). You can read the full report and learn more about the key takeaways for business at About PwC At PwC, we help clients build trust and reinvent so they can turn complexity into competitive advantage. We're a tech-forward, people-empowered network with more than 370,000 people in 149 countries. Across audit and assurance, tax and legal, deals and consulting we help build, accelerate and sustain momentum. Find out more at SOURCE PwC
Cision Canada
an hour ago
- Cision Canada
Blokees Initial Release Minions Mokoo Series: Minions-N-Disguise, Becomes a Banana Day Hotspot
SHANGHAI, June 3, 2025 /CNW/ -- On June 1, 2025, the 2025 Minions Banana Day was officially launched in Shanghai and Beijing, marking the commencement of a five-month tour across six cities in China. The Chinese building block character toy brand Blokees made a special appearance at the event. At the flagship station in Shanghai, Blokees globally unveiled and simultaneously made available to purchase its latest Minions Mokoo Series: Minions-N-Disguise. This series showcases six iconic Minions characters: King Bob, Soldier Stuart, Golf Tim, Knight Dave, Maid Phil, and Caveman Kevin. Their distinctive physical traits and classic appearances are meticulously replicated. Each figure features detachable outfits, interchangeable accessories, and 11 articulated joints, enabling engaging and realistic interaction. In addition, a hidden cute skeleton design serves as a surprising Easter egg, offering an unexpected delight to dedicated Minions fans. Blokees has been actively promoting user innovation, further cultivating the innovative culture of the BFC (Blokees Figures Creator) brand, and encouraging users to become creators within the BFC ecosystem. In the Minions Banana Day exhibition area, Blokees has specifically established a dedicated display zone for BFC creations. The Blokees booth attracted considerable attention and became a prominent destination for Minions enthusiasts. Attendees participated in photo sessions and group portraits while experiencing the innovative process of construction and transformation. The atmosphere was lively, characterized by laughter and enthusiasm. A dedicated Minions fan commented with excitement, "These Minions building blocks exhibit highly detailed and realistic designs, offering versatility through customizable outfits. The integration of a skeletal framework represents an ingenious and surprising feature, enhancing the product's appeal significantly." The Minions Banana Day will continue until October 26, making stops in Shanghai, Beijing, Chengdu, Wuhan, Changsha, and Shenyang. Throughout the tour, Blokees will introduce additional Minions-themed releases and interactive activities. With a portfolio encompassing over 500 patents, Blokees remains at the forefront of innovation. Through its "All Ages, All Price Points, Global Reach" strategy, Blokees is progressively propelling Chinese brick-based character toys onto the global stage.
Cision Canada
an hour ago
- Cision Canada
Experimental Drug Development Centre Announces the Presentation of Updated Data from the Phase 1 Study of Antibody-Drug Conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)
EBC-129 is an antibody-drug conjugate (ADC) that selectively targets a novel, tumour-specific N-glycosylated epitope found on both CEACAM5 and CEACAM6. The expansion cohort for pancreatic ductal adenocarcinoma (PDAC) in the ongoing Phase 1 trial has completed enrolment. Notably, 82% of patients had tumours expressing the antigen at levels considered treatable with EBC-129. EBC-129 demonstrated positive overall response rates and prolonged progression-free survival in PDAC patients that have been heavily pre-treated, including those that have received prior treatment with standard of care (SoC) typically containing taxanes. The US FDA also recently granted Fast Track Designation for EBC-129 in the treatment of PDAC patients. SINGAPORE, June 3, 2025 /CNW/ -- The Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, has announced the presentation of updated clinical data for the ongoing Phase 1 trial for EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. EBC-129 is a first-in-class antibody drug conjugate (ADC) targeting a novel, tumour-specific N256-glycosylated epitope on CEACAM5 and CEACAM6. The updated findings showed promising efficacy data from 21 heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patients across the dose escalation and the dose expansion portions of the Phase 1 study. Patients received EBC-129 at doses between 1.8 and 2.2 mg/kg, given once every 3 weeks. 17 out of 21 patients (81%) of the patients had received prior treatment with taxanes. 82% of patients had tumours which expressed the EBC-129 antigen at ≥1% at 3+ intensity and were therefore considered treatable. The overall response rates (ORRs) were 25% and 20%, with disease control rates (DCRs) of 87.5% and 63.6% and progression-free survival (PFS) of 19 and 12 weeks for 1.8 mg/kg and 2.2 mg/kg, respectively. "Pancreatic adenocarcinoma remains one of the most challenging cancers to treat, particularly in the metastatic setting where resistance to standard therapies is common. The clinical signals observed with EBC-129 in refractory pancreatic adenocarcinoma, including tolerability, prolonged disease control and a confirmed response in a heavily pre-treated patient, are encouraging and clinically meaningful. Continued prioritisation of biology-guided trials targeting EBC-129 will be key to sustaining momentum in this important therapeutic effort," said Assistant Professor Robert W. Lentz, MD, Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz School of Medicine. This presentation follows the recent Fast Track Designation granted by the U.S. FDA for EBC-129 in the treatment of PDAC patients. This designation supports EDDC's efforts to accelerate the advancement of the programme through increased regulatory engagement and the potential for expedited review pathways. Other Results to Date The dose escalation study of the Phase 1 trial was open to all patients, while the ongoing dose expansion study comprises of three cohorts in PDAC, gastroesophageal adenocarcinoma (GEA) and tumour-agnostic patients with other immunohistochemistry (IHC)-positive solid tumours. Recruitment for the GEA and IHC-positive cohorts is still ongoing. EBC-129 showed a manageable safety profile in the 58 patients treated so far, with uncomplicated neutropenia and infusion-related reactions as the main treatment-related adverse events (TRAEs) observed. The EBC-129 antigen was also found to be highly expressed, with 52% to 100% of tumour tissues assessed during the trial showing moderate to high expression levels of ≥20% at 2+ and/or 3+. This included samples from gastroesophageal, appendiceal, colorectal and lung cancer patients, making EBC-129 a potentially viable treatment option for these cancers. "We have seen encouraging signs of efficacy of EBC-129 as a single-agent therapy, even in heavily pre-treated patients with metastatic pancreatic cancer. This, combined with the observed safety profile, underscores the promise of EBC-129 as a possible treatment option for PDAC patients. As a first-in-class ADC that targets both CEACAM5 and CEACAM6, EBC-129 has also shown potential against a range of other solid tumours, and we look forward to expanding clinical evaluations with the ongoing dose expansion cohorts and accelerating the development of EBC-129 to address critical unmet needs in cancer," said Professor Damian O'Connell, CEO of EDDC. About EBC-129 EBC-129 is an ADC that targets a tumour-specific N256-glycosylation site conserved on CEACAM5 and CEACAM6. CEACAM5 and CEACAM6 are known to have functional importance in tumour formation, migration and metastasis. In the ongoing trial, the tumour-specific marker is found to be widely expressed in multiple solid tumour types, including gastric, oesophageal, pancreatic, lung, colorectal, and appendiceal cancers, based on an analytically validated immunohistochemistry (IHC) assay. The payload used in EBC-129 is monomethyl auristatin E (MMAE), which has been extensively tested and approved for clinical use in other marketed ADCs, and has demonstrated synergy with PD-1 inhibitors. The ongoing Phase 1 trial of EBC-129 is assessing the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours. Enrolment for the PDAC cohort in the Phase 1 dose expansion study is now complete, while recruitment continues for the gastroesophageal adenocarcinoma (GEA) and IHC-positive cohorts. About the Experimental Drug Development Centre The Experimental Drug Development Centre (EDDC) is Singapore's national platform for drug discovery and development, formed from the integration of the Experimental Therapeutics Centre (ETC), Drug Discovery and Development (D3), and Experimental Biotherapeutics Centre (EBC) in 2019. EDDC aims to develop therapeutics and diagnostics that save and improve the lives of patients in Singapore, Asia and around the world. Hosted by the Agency for Science, Technology and Research (A*STAR), EDDC works collaboratively with public sector and industry partners to translate the great science arising from Singapore's biomedical and clinical sciences R&D into innovative healthcare solutions. For more information about EDDC, please visit
